About the Company
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LJPC News
La Jolla Stock Plummets 44% After Disappointing Drug Sales Projections
La Jolla Pharmaceutical Co.'s share price fell to $5.88 by 1:42 pm, down from its close of $10.52 on Friday, after the company said it expects sales of low blood pressure drug Giapreza to hit $24 ...
La Jolla Pharmaceutical Co
NOTE: All lobbying expenditures on this page come from the Senate Office of Public Records. Data for the most recent year was downloaded on January 23, 2021. Feel free to distribute or cite this ...
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein ...
Antimicrobial resistance: Shionogi advocates policy change to address the public health threat
Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical Company. Simply put, the market for antibiotics that address AMR is broken. Shionogi strongly supports the introduction of new ...
La Jolla Institute for Immunology, RevolKa to start research collaboration to create antigens for next-generation vaccines
La Jolla Institute for Immunology, RevolKa to start research collaboration to create antigens for next-generation vaccines: Tokyo Monday, April 22, 2024, 14:00 Hrs [IST] RevolKa L ...
Johnson & Johnson, Pfizer, Eli Lilly and other big pharmas are backing this San Diego biotech with $175M
Thanks to that novel approach and the support of some of the biggest names in the pharmaceutical ... The company has 79 ...
Could HIV drugs help keep Alzheimer’s at bay?
A recent study suggests that a type of drugs commonly used to treat HIV are also associated with a lower incidence of ...
Dr Leon Lachman OBITUARY
Leon Lachman died on Wednesday, March 13, 2024, at 95 years of age, at his home in La Jolla, California ... and Master’s Degree in Pharmacy and Pharmaceutical Sciences. He then went on to ...
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., April 03 ... with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd., for the development and commercialization of itolizumab under an ...
Loading the latest forecasts...